Testosterone Therapy

Testosterone therapy in men with hypogonadism prevents progression from prediabetes to Type 2 diabetes: eight year data from a registry study.  40% of those in the untreated group progressed to type 2 diabetes.  Improvements in fasting glucose, triglyceride to HDL ratio, triglyceride-glucose index, total cholesterol, LDL, HDL, non-HDL & triglycerides.  Mortality was 7.4% in the Testosterone group and 16.1% in the untreated group.  The incidence of nonfatal heart attack was 0.4% in the treated group and 5.7% in the untreated group.  Long-term testosterone therapy prevents the progression of prediabetes to Type 2 DM in males.

Diabetes Care. 2019; 42:1104-1111.